PortfoliosLab logoPortfoliosLab logo
HALO vs. MELI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

HALO vs. MELI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Halozyme Therapeutics, Inc. (HALO) and MercadoLibre, Inc. (MELI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, HALO achieves a 3.27% return, which is significantly higher than MELI's -21.08% return. Over the past 10 years, HALO has underperformed MELI with an annualized return of 22.84%, while MELI has yielded a comparatively higher 28.09% annualized return.


HALO

1D
-1.74%
1M
0.42%
YTD
3.27%
6M
11.72%
1Y
28.75%
3Y*
27.10%
5Y*
10.19%
10Y*
22.84%

MELI

1D
-1.27%
1M
-1.11%
YTD
-21.08%
6M
-21.15%
1Y
-32.98%
3Y*
9.54%
5Y*
2.68%
10Y*
28.09%
*Multi-year figures are annualized to reflect compound growth (CAGR)

HALO vs. MELI - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
HALO
Halozyme Therapeutics, Inc.
3.27%40.77%29.36%-35.04%41.51%-5.85%140.89%21.19%-27.79%105.06%
MELI
MercadoLibre, Inc.
-21.08%18.46%8.20%85.71%-37.24%-19.51%192.90%95.30%-6.93%101.99%

Correlation

The correlation between HALO and MELI is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.06

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.25

Correlation (10Y)
Calculated over the trailing 10-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Aug 10, 2007

0.30

Over the past year, the correlation between HALO and MELI has dropped to 0.06 - well below their long-term average of 0.30, suggesting their price drivers have been diverging.

Fundamentals

Market Cap

HALO:

$8.54B

MELI:

$80.59B

EPS

HALO:

$2.87

MELI:

$37.87

PE Ratio

HALO:

24.26

MELI:

41.97

PEG Ratio

HALO:

2.74

MELI:

0.25

PS Ratio

HALO:

5.61

MELI:

2.63

PB Ratio

HALO:

38.88

MELI:

11.07

Total Revenue (TTM)

HALO:

$1.51B

MELI:

$30.67B

Gross Profit (TTM)

HALO:

$1.23B

MELI:

$13.95B

EBITDA (TTM)

HALO:

$980.05M

MELI:

$3.11B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

HALO vs. MELI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HALO
HALO Risk / Return Rank: 6666
Overall Rank
HALO Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
HALO Sortino Ratio Rank: 6666
Sortino Ratio Rank
HALO Omega Ratio Rank: 6464
Omega Ratio Rank
HALO Calmar Ratio Rank: 6666
Calmar Ratio Rank
HALO Martin Ratio Rank: 6464
Martin Ratio Rank

MELI
MELI Risk / Return Rank: 1111
Overall Rank
MELI Sharpe Ratio Rank: 99
Sharpe Ratio Rank
MELI Sortino Ratio Rank: 1212
Sortino Ratio Rank
MELI Omega Ratio Rank: 1111
Omega Ratio Rank
MELI Calmar Ratio Rank: 1212
Calmar Ratio Rank
MELI Martin Ratio Rank: 99
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HALO vs. MELI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and MercadoLibre, Inc. (MELI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


HALOMELIDifference
Sharpe ratioReturn per unit of total volatility

+1.75

Sortino ratioReturn per unit of downside risk

+2.44

Omega ratioGain probability vs. loss probability

1.17

0.86

+0.31

Calmar ratioReturn relative to maximum drawdown

1.14

-0.81

+1.95

Martin ratioReturn relative to average drawdown

2.16

-1.42

+3.58

HALO vs. MELI - Sharpe Ratio Comparison

The current HALO Sharpe Ratio is 0.91, which is higher than the MELI Sharpe Ratio of -0.84. The chart below compares the historical Sharpe Ratios of HALO and MELI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

HALO vs. MELI - Drawdown Comparison

The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum MELI drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for HALO and MELI.


Loading charts...

Drawdown Indicators


HALOMELIDifference

Max Drawdown

Largest peak-to-trough decline

-74.26%

-89.49%

+15.23%

Max Drawdown (1Y)

Largest decline over 1 year

-24.13%

-40.82%

+16.69%

Max Drawdown (3Y)

Largest decline over 3 years

-33.92%

-40.82%

+6.90%

Max Drawdown (5Y)

Largest decline over 5 years

-49.06%

-68.64%

+19.58%

Max Drawdown (10Y)

Largest decline over 10 years

-49.06%

-69.12%

+20.06%

Current Drawdown

Current decline from peak

-14.44%

-39.18%

+24.74%

Average Drawdown

Average peak-to-trough decline

-31.88%

-23.58%

-8.30%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.73%

23.24%

-10.51%

Volatility

HALO vs. MELI - Volatility Comparison

The current volatility for Halozyme Therapeutics, Inc. (HALO) is 8.94%, while MercadoLibre, Inc. (MELI) has a volatility of 9.96%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than MELI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


HALOMELIDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.94%

9.96%

-1.02%

Volatility (6M)

Calculated over the trailing 6-month period

24.02%

29.79%

-5.77%

Volatility (1Y)

Calculated over the trailing 1-year period

30.20%

39.48%

-9.28%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

39.42%

49.65%

-10.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

42.88%

48.88%

-6.00%

Dividends

HALO vs. MELI - Dividend Comparison

Neither HALO nor MELI has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
HALO
Halozyme Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MELI
MercadoLibre, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.19%0.38%0.36%

Financials

HALO vs. MELI - Financials Comparison

This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and MercadoLibre, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B20222023202420252026
376.71M
7.72B
(HALO) Total Revenue
(MELI) Total Revenue
Values in USD except per share items

HALO vs. MELI - Profitability Comparison

The chart below illustrates the profitability comparison between Halozyme Therapeutics, Inc. and MercadoLibre, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%20222023202420252026
79.0%
50.1%
Portfolio components
HALO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.

MELI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, MercadoLibre, Inc. reported a gross profit of 3.86B and revenue of 7.72B. Therefore, the gross margin over that period was 50.1%.

HALO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.

MELI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, MercadoLibre, Inc. reported an operating income of 611.00M and revenue of 7.72B, resulting in an operating margin of 7.9%.

HALO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.

MELI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, MercadoLibre, Inc. reported a net income of 417.00M and revenue of 7.72B, resulting in a net margin of 5.4%.


Frequently Asked Questions


HALO and MELI have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MELI has higher volatility (9.96%) compared to HALO (8.94%). In terms of maximum drawdown, HALO dropped -74.26% vs MELI's -89.49%.

HALO currently has the higher Sharpe Ratio (0.91 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for HALO and MELI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer